Biotech firm LyGenesis raises $3 million in funding for regenerative tissue work
Flipping the Script on Organ Regeneration
A University of Pittsburgh spin out company offers a remarkable prospect for people with a disease-ridden liver: a way to make a new liver.
Like something from a science fiction novel, LyGenesis Inc. claims to have come up with a way to create working liver tissue in patients whose organs have been destroyed by disease. Investors are feeling the buzz.
Lagasse said there are about 20,000 people waiting for liver transplants, which represents only a fraction of people suffering from liver disease who could benefit from the treatment. Depending on the stage of the disease, ectopic liver generation treatment could serve as a bridge to a transplant, or if done early enough in the disease progression, eliminate the eventual need for a transplant.